Longevica reports a four-year, $13 million in vivo screen at The Jackson Laboratory that followed more than 16,000 mice across their natural lifespans while testing 1,033 small molecules, with over 60 compounds claimed to extend mammalian lifespan by 10–22%. The compounds remain unnamed and the underlying data unpublished, leaving the findings unverifiable outside the company. A new chief executive and a twelve-member advisory board signal a shift from discovery toward preclinical and eventual clinical development.
Key Points
- 16,000 mice, 1,033 compounds screened across full natural lifespans
- Over 60 compounds reported to extend lifespan 10–22%
- Compound identities and underlying data not yet disclosed publicly
Longevity Analysis
Full-lifespan mammalian data carries more weight than cell lines, short-lived invertebrates or retrospective mining, because survival is measured rather than inferred from a proxy marker. The proposed disease-directed arm — cardiovascular, metabolic and fibrotic conditions — reflects the practical reality that pharmacological lifespan extension must translate into preserved circulatory function, metabolic efficiency and tissue repair capacity to matter clinically. Until compound identities and survival curves are published, the appropriate posture is attentive skepticism: unverifiable preclinical claims should not displace the interventions already demonstrated to reduce biological interference and support healthspan in humans.
Original published by Longevity.Technology, by Kyle Umipig.